These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30247596)

  • 1. Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
    Weinberg A; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Levin MJ
    J Infect Dis; 2018 Sep; 218(suppl_2):S81-S87. PubMed ID: 30247596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th1 memory differentiates recombinant from live herpes zoster vaccines.
    Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
    J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence.
    Johnson MJ; Liu C; Ghosh D; Lang N; Levin MJ; Weinberg A
    J Infect Dis; 2022 Apr; 225(8):1477-1481. PubMed ID: 34850039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
    Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
    J Virol; 2021 May; 95(12):. PubMed ID: 33762414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
    Chlibek R; Pauksens K; Rombo L; van Rijckevorsel G; Richardus JH; Plassmann G; Schwarz TF; Catteau G; Lal H; Heineman TC
    Vaccine; 2016 Feb; 34(6):863-8. PubMed ID: 26432913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
    Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
    Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Benson CA; Andersen JW; Macatangay BJC; Mailliard RB; Rinaldo CR; Read S; Bozzolo DR; Purdue L; Jennings C; Keefer MC; Glesby M; Tebas P; Russell AF; Martin J; Annunziato P; Popmihajlov Z; Lennox JL
    Clin Infect Dis; 2018 Nov; 67(11):1712-1719. PubMed ID: 29590326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
    Weinberg A; Canniff J; Rouphael N; Mehta A; Mulligan M; Whitaker JA; Levin MJ
    J Immunol; 2017 Jul; 199(2):604-612. PubMed ID: 28607114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
    Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
    Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
    Berkowitz EM; Moyle G; Stellbrink HJ; Schürmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC;
    J Infect Dis; 2015 Apr; 211(8):1279-87. PubMed ID: 25371534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.